CLINICAL AND EPIDEMIOLOGICAL FEATURES OF THE COURSE OF CORONAVIRUS INFECTION DEPENDING ON THE PERIOD OF ILLNESS
DOI:
https://doi.org/10.11603/1681-2727.2024.3.14874Keywords:
COVID-19, Long COVID, SARS-CoV-2, features, epidemiology, good healthAbstract
After the COVID-19 pandemic, the persistence of Long COVID symptoms is of particular concern, which significantly affects the quality of life and ability to work.
The aim of the study is to establish the peculiarities of clinical and epidemiological data in patients infected with SARS-CoV-2 depending on the period of illness.
Patients and methods. We examined 108 patients divided into three groups: those with confirmed COVID-19, those with Long COVID, and practically healthy persons. The epidemiological and clinical features of the course were determined based on the analysis of medical records and the developed questionnaire.
Results. Women predominated among the study subjects (56 %) with an average age of 41.44 years. The main symptoms that characterized the clinical picture of COVID-19 were generalized weakness/fatigue (94 %), headache (74 %), fever/body aches and cough in 71 % of patients (p<0.05). In the Long COVID group, compared to the COVID-19 group, generalized weakness/fatigue (40 %), headache (29 %), fever/body aches (3 %), and cough (9 %) were significantly less common, sleep disorders / insomnia (17 %), muscle pain (11 %), shortness of breath (17 %), runny nose / sneezing (6 %), loss (worsening) of appetite (3 %), sore throat (6 %), difficulty concentrating (6 %), abdominal pain (3 %) (p<0.05).
Conclusions. Reduced access to healthcare services leads to delayed hospitalization, prolonged treatment, and complications.
The level of vaccination does not affect the risk of Long COVID.
Clinical signs of Long COVID: generalized weakness/fatigue, anxiety, mood disturbance, headache are detected in one third of patients and cause a decrease in overall quality of life. The most persistent are general weakness/fatigue, headache, shortness of breath, sleep disorders/insomnia and persist in 34-42 % of patients from the moment COVID-19 is confirmed.
References
Tsilingiris, D., Vallianou, N. G., Karampela, I., Christodoulatos, G. S., Papavasileiou, G., Petropoulou, D., Magkos, F., & Dalamaga, M. (2023). Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges. International journal of molecular sciences, 24(13), 10458. https://doi.org/10.3390/ijms241310458. DOI: https://doi.org/10.3390/ijms241310458
Tsilingiris, D., Vallianou, N. G., Karampela, I., Liu, J., & Dalamaga, M. (2022). Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabolism open, 13, 100159. https://doi.org/10.1016/j.metop.2021.100159. DOI: https://doi.org/10.1016/j.metop.2021.100159
Andreychyn, M. A., Nychyk, N. A., Zavidniuk, N. H., Iosyk, I. I., Ischuk, I. S., & Ivakhiv, O. L. (2020). COVID-19: epidemiology, clinics, diagnosis, treatment and prevention. Infectious Diseases – Infektsiyni Khvoroby, (2), 41–55. https://doi.org/10.11603/1681-2727.2020.2.11285 [in Ukrainian]. DOI: https://doi.org/10.11603/1681-2727.2020.2.11285
Sumtsova, K., Berezhok, V., Lishnevska, A., & Chemych, M. (2024). The Dependence Of Changes In Laboratory Indicators On Accompanying Pathology In Patients With Viral Hepatitis C. Eastern Ukrainian Medical Journal, 12(1), 69-80. https://doi.org/10.21272/eumj.2024;12(1):69-80 [in Ukrainian]. DOI: https://doi.org/10.21272/eumj.2024;12(1):69-80
Siddiqui, S., Alhamdi, H. W. S., & Alghamdi, H. A. (2022). Recent Chronology of COVID-19 Pandemic. Frontiers in public health, 10, 778037. https://doi.org/10.3389/fpubh.2022.778037. DOI: https://doi.org/10.3389/fpubh.2022.778037
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023). Long COVID: major findings, mechanisms and recommendations. Nature reviews. Microbiology, 21(3), 133–146. https://doi.org/10.1038/s41579-022-00846-2. DOI: https://doi.org/10.1038/s41579-022-00846-2
Tsampasian, V., Elghazaly, H., Chattopadhyay, R., Debski, M., Naing, T. K. P., Garg, P., Clark, A., Ntatsaki, E., & Vassiliou, V. S. (2023). Risk Factors Associated with Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA internal medicine, 183(6), 566–580. https://doi.org/10.1001/jamainternmed.2023.0750. DOI: https://doi.org/10.1001/jamainternmed.2023.0750
Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, I., & Dalamaga, M. (2022). Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabolism open, 14, 100180. https://doi.org/10.1016/j.metop.2022.100180. DOI: https://doi.org/10.1016/j.metop.2022.100180
Ayoubkhani, D., Bosworth, M. L., King, S., Pouwels, K. B., Glickman, M., Nafilyan, V., Zaccardi, F., Khunti, K., Alwan, N. A., & Walker, A. S. (2022). Risk of Long COVID in People Infected with Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study. Open forum infectious diseases, 9(9), ofac464. https://doi.org/10.1093/ofid/ofac464. DOI: https://doi.org/10.1093/ofid/ofac464
Al-Aly, Z., Bowe, B., & Xie, Y. (2022). Long COVID after breakthrough SARS-CoV-2 infection. Nature medicine, 28(7), 1461-1467. https://doi.org/10.1038/s41591-022-01840-0. DOI: https://doi.org/10.1038/s41591-022-01840-0
Tsuchida, T., Hirose, M., Inoue, Y., Kunishima, H., Otsubo, T., & Matsuda, T. (2022). Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. Journal of medical virology, 94(7), 3416-3420. https://doi.org/10.1002/jmv.27689. DOI: https://doi.org/10.1002/jmv.27689
Chen, C., Haupert, S. R., Zimmermann, L., Shi, X., Fritsche, L. G., & Mukherjee, B. (2022). Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. The Journal of infectious diseases, 226(9), 1593-1607. https://doi.org/10.1093/infdis/jiac136. DOI: https://doi.org/10.1093/infdis/jiac136
Michelen, M., Manoharan, L., Elkheir, N., Cheng, V., Dagens, A., Hastie, C., O’Hara, M., Suett, J., Dahmash, D., Bugaeva, P., Rigby, I., Munblit, D., Harriss, E., Burls, A., Foote, C., Scott, J., Carson, G., Olliaro, P., Sigfrid, L., & Stavropoulou, C. (2021). Characterising long COVID: a living systematic review. BMJ global health, 6(9), e005427. https://doi.org/10.1136/bmjgh-2021-005427. DOI: https://doi.org/10.1136/bmjgh-2021-005427
Svitailo, V. S., Chemych, M. D., Saienko, O. S. (2023). LONG-COVID and associated cardiovascular and nervous system disorders. Infectious diseases – Infektsiyni khvoroby, 4, 49-54. https://doi.org/10.11603/1681-2727.2022.4.13701 [in Ukrainian]. DOI: https://doi.org/10.11603/1681-2727.2022.4.13701
Saienko, O., Chemych, M., Svitailo, V. (2023). Long-COVID, neurological and cardiovascular disorders. Journal of Education, Health and Sport, 13(3), 381-393. http://dx.doi.org/10.12775/JEHS.2023.13.03.048. DOI: https://doi.org/10.12775/JEHS.2023.13.03.048
Oliveira, M., Ferreira Coelho, A., Lourenço, C., Campos Pinto, F., Atabão, I., Cabrita, J., Paraíso, R., Mesquita, R., Torrado, E., Marquez, D., & Guerreiro, V. (2023). Long COVID Symptoms in Non-Hospitalised Patients: A Retrospective Study. Acta Médica Portuguesa, 36(10), 618–630. https://doi.org/10.20344/amp.19566. DOI: https://doi.org/10.20344/amp.19566
Downloads
Published
Issue
Section
License
Copyright (c) 2024 О. С. Саєнко, М. Д. Чемич
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
